DekaBank Deutsche Girozentrale
APRE icon

DekaBank Deutsche Girozentrale’s Aprea Therapeutics APRE Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-350
Closed -$34K – 1389
2021
Q1 		$34K Hold
350
– – ﹤0.01% 1316
2020
Q4 		$35K Buy
+350
New +$166K ﹤0.01% 1303

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

DekaBank Deutsche Girozentrale's APRE Position: Q2 2021 in Review

DekaBank Deutsche Girozentrale sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 350 shares — an estimated $34K sold.

DekaBank Deutsche Girozentrale first reported a position in APRE in Q4 2020 and held it in 2 quarters. The position peaked at $35K in Q4 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 350 Aprea Therapeutics shares in Q2 2021, an estimated $34K.
  • DekaBank Deutsche Girozentrale first reported a position in Aprea Therapeutics in Q4 2020 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's Aprea Therapeutics position peaked at $35K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2021, filed 5 Aug 2021.